Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | PRNP | P04156 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.32 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16719118 | 0.79 | PDE10A (0.35) | MAPTPRNPHTTALDH1A1RXFP1 | |
| SCHEMBL16719083 | 0.75 | CCNB2 (0.30) | RPS6KA5 | |
| SCHEMBL13348648 | 0.74 | HPGD (0.35) | NQO2MAPTPRNPNPSR1LMNA | |
| SCHEMBL24154377 | 0.74 | RPS6KA5 (0.32) | RPS6KA5NPC1RAB9AKMT2A | |
| SCHEMBL2513088 | 0.70 | MAPT (0.44) | NQO2MAPTPRNPHPGDALDH1A1 | |
| SCHEMBL30217623 | 0.70 | MAPT (0.44) | NQO2MAPTPRNPHPGDALDH1A1 | |
| SCHEMBL27166952 | 0.67 | NQO2 (0.46) | NQO2MAPTPRNPNPSR1LMNA | |
| SCHEMBL24153281 | 0.67 | NQO2 (0.45) | NQO2MAPTPRNPNPSR1LMNA | |
| SCHEMBL30408222 | 0.67 | NQO2 (0.45) | NQO2MAPTPRNPNPSR1LMNA | |
| SCHEMBL31259133 | 0.66 | NQO2 (0.54) | NQO2MAPTPRNPNPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024109660-A1 | CDK INHIBITORS | 上海齐鲁制药研究中心有限公司 | 2024-05-30 | — | — | WO | disclosed |
| US-20230219934-A1 | 2,3-DISUBSTITUTED PYRIDO[3,4-B]PYRAZINE-CONTAINING COMPOUNDS AS KINASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219934-A1 | 2,3-DISUBSTITUTED PYRIDO[3,4-B]PYRAZINE-CONTAINING COMPOUNDS AS KINASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219934-A1 | 2,3-DISUBSTITUTED PYRIDO[3,4-B]PYRAZINE-CONTAINING COMPOUNDS AS KINASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2023-07-13 | — | — | US | disclosed |
| EP-4175957-A1 | 2,3-DISUBSTITUTED PYRIDO[3,4-B]PYRAZINE-CONTAINING COMPOUNDS AS KINASE INHIBITORS | Purdue Research Foundation (US) | 2023-05-10 | — | — | EP | disclosed |
| WO-2021262915-A1 | 2,3-DISUBSTITUTED PYRIDO[3,4-B]PYRAZINE-CONTAINING COMPOUNDS AS KINASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021262915-A1 | 2,3-DISUBSTITUTED PYRIDO[3,4-B]PYRAZINE-CONTAINING COMPOUNDS AS KINASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219934-A1 | 2,3-DISUBSTITUTED PYRIDO[3,4-B]PYRAZINE-CONTAINING COMPOUNDS AS KINASE INHIBITORS | MAP3K2, MAP4K2, MAP3K5 | NQO2 1523/4885MAPT 1649/4885PRNP 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.